Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
Press Release Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update More patients on ...
Mitsubishi Tanabe Pharma America to Showcase New Research Findings in ALS at 2025 MDA Clinical and Scientific Conference
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...
Yahoo Finance12d
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
The last patient in the ongoing Whistler Phase 3b clinical trial investigating NCX 470’s dual mechanism of action (nitric oxide and prostaglandin analog) in IOP lowering is now expected to ...
Healio26d
Tildrakizumab shows long-term scalp psoriasis improvement
This phase 3b clinical trial focused on safety and efficacy of the anti-IL-23 inhibitor in scalp psoriasis. Patients taking tildrakizumab had scalp improvement by 16 weeks, which continued through ...
European Medical Journal17d
New Evidence Supports Tildrakizumab for Scalp Psoriasis
Discover a study where patients initially receiving placebo experienced notable improvement after switching to tildrakizumab.
GEN - Genetic Engineering and Biotechnology News2d
Roche, Zealand Launch Up-to-$5.3B Obesity Collaboration
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...
BioWorld3d
Roche, Zealand pact for up to $5.3B is focused on new obesity drug
Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...